Yosuke Sasaki

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma

Kensei Tobinai, Yukio Kobayashi, Masaru Narabayashi et al. · Annals of Oncology · 1998 · 151 citations · Full text

B-cell Lymphoma, Lymphoid Neoplasia, Hematological Malignancy +7

Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.

T. Ohtsu, Yosuke Sasaki, Tomohiro Tamura et al. · PubMed · 1995 · 144 citations

Peripheral Neuropathy, 24-Hour Infusion, Pharmacokinetic Modeling +13

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

Tomofumi Igarashi, Yukio Kobayashi, Michinori Ogura et al. · Annals of Oncology · 2002 · 138 citations · Full text

Hematological Malignancy, Indolent B-cell Lymphoma, Progression-free Survival +10

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer

Wataru Ichikawa, Hiroyuki Uetake, Yoshinori Shirota et al. · British Journal of Cancer · 2003 · 128 citations · Full text

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

K. Aogi, Hiroji Iwata, Norikazu Masuda et al. · Annals of Oncology · 2011 · 122 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +8